MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/iju5.70203

Медицинская библиотека · IJU case reports · 2026

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma.

Soga Erika, Noguchi Go, Kobayashi Kota, Shibata Rio, Jikuya Ryosuke, Tatenuma Tomoyuki, Komeya Mitsuru, Ito Hiroki, Hasumi Hisashi, Makiyama Kazuhide

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Lenvatinib plus pembrolizumab is a standard first-line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event.

CASE PRESENTATION: A 60-year-old woman with metastatic TFE3-positive non-clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (IMDC) criteria, started pembrolizumab plus lenvatinib after palliative radiotherapy for cervical spine metastasis. Lenvatinib was initiated at 8 mg and escalated to 12 mg, achieving tumor shrinkage. Nine days after starting cycle 4, she developed fever and right upper quadrant pain. Computed tomography demonstrated gallbladder distension and wall thickening without gallstones, consistent with acute acalculous cholecystitis. Lenvatinib was interrupted, and intravenous piperacillin/tazobactam was administered; her symptoms improved without drainage. Lenvatinib was resumed at 8 mg with pembrolizumab, and no recurrence occurred.

CONCLUSION

Early recognition and temporary interruption of lenvatinib with antibiotics may allow cautious rechallenge.

Для цитирования: Soga Erika, Noguchi Go, Kobayashi Kota, Shibata Rio, Jikuya Ryosuke, Tatenuma Tomoyuki, Komeya Mitsuru, Ito Hiroki, Hasumi Hisashi, Makiyama Kazuhide. A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma.. IJU case reports. 2026. DOI: 10.1002/iju5.70203.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.